Home › Research › Brain scans and imaging
Tau PET imaging in Black and Latino participants with and without cognitive impairment
Gregory Scott Day, Scott A. Przybelski, Manoj K Jain, Christian Lachner, Yoav D. Piura, Paula A. Aduen, Leah Schecter, Angela J. Fought et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Eighty-three Black (mean 72±10.8-years-old, 63% female, 33% cognitively impaired) and 27 Latino participants (mean 65.8-years-old, 56% female, 11% cognitively impaired) completed neuroimaging. Data were compared with findings in 110 matched nHW individuals. Global tau-PET burden was similar between matched cohorts (Black and nHW participants, mean SUVR: 1.34±0.39 vs 1.36±0.37, p = 0.71; Latino and nHW participants, mean SUVR: 1.17±0.09 vs 1.20±0.11, p = 0.66). Lower flortaucipir uptake was noted in the caudate (p = 0.005) and putamen (p = 0.022) of Black/Latino participants (vs nHW), although differences attenuated following adjustment for white matter hyperintensity volume. Global flortaucipir retention increased with age (Black: Rho=0.31; Latino: Rho=0.46; nHW: Rho=0.27; p <0.05), amyloid Centiloids (Black: Rho=0.65; Latino: Rho=0.41; nHW: Rho=0.58; p <0.05), and cognitive impairment (i.e., Clinical Dementia Rating® Sum-of-Box scores, Black/Latino: Rho=0.31, p = 0.07; nHW: 0.76, p <0.001). Tau-PET patterns were similar across ethnoracial groups after adjusting for white matter hyperintensity volumes-a biomarker of small vessel disease. Flortaucipir retention increased with age, amyloid accumulation, and cognitive impairment across all cohorts. These findings affirm the clinical and research applications of tau PET in diverse cohorts. ACKNOWLEDGEMENTS: Flortaucipir precursor and technology was supported by Avid Radiopharmaceuticals.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 83 participants. This study found that tau PET patterns were similar across Black, Latino, and non-Hispanic white participants after adjusting for a marker of small vessel disease. It supports the use of tau PET in diverse groups and does not test any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Day, G. S., Przybelski, S. A., Jain, M. K., Lachner, C., Piura, Y. D., Aduen, P. A., et al. (2025). Tau PET imaging in Black and Latino participants with and without cognitive impairment. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_106309
Vancouver
Day GS, Przybelski SA, Jain MK, Lachner C, Piura YD, Aduen PA, et al. Tau PET imaging in Black and Latino participants with and without cognitive impairment. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_106309. PMID: 41513292.
BibTeX
@article{day2025-41513292,
author = {Day, Gregory Scott and Przybelski, Scott A. and Jain, Manoj K and Lachner, Christian and Piura, Yoav D. and Aduen, Paula A. and Schecter, Leah and Fought, Angela J. and others},
title = {{Tau PET imaging in Black and Latino participants with and without cognitive impairment}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_106309},
pmid = {41513292},
url = {https://doi.org/10.1002/alz70856_106309}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Eighty-three Black (mean 72±10.8-years-old, 63% female, 33% cognitively impaired) and 27 Latino participants (mean 65.8-years-old, 56% female, 11% cognitively impaired) completed neuroimaging.
- Data were compared with findings in 110 matched nHW individuals.
- Global tau-PET burden was similar between matched cohorts (Black and nHW participants, mean SUVR: 1.34±0.39 vs 1.36±0.37, p = 0.71; Latino and nHW participants, mean SUVR: 1.17±0.09 vs 1.20±0.11, p = 0.66).
- Lower flortaucipir uptake was noted in the caudate (p = 0.005) and putamen (p = 0.022) of Black/Latino participants (vs nHW), although differences attenuated following adjustment for white matter hyperintensity volume.
- Global flortaucipir retention increased with age (Black: Rho=0.31; Latino: Rho=0.46; nHW: Rho=0.27; p <0.05), amyloid Centiloids (Black: Rho=0.65; Latino: Rho=0.41; nHW: Rho=0.58; p <0.05), and cognitive impairment (i.e., Clinical Dementia Rating® Sum-of-Box scores, Black/Latino: Rho=0.31, p = 0.07; nHW: 0.76, p <0.001).
Why it matters
This study found that tau PET patterns were similar across Black, Latino, and non-Hispanic white participants after adjusting for a marker of small vessel disease. It supports the use of tau PET in diverse groups and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Study designlongitudinal study
- Participants83
- Evidence strengthModerate
How this study scored 48/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 83 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Neill R. Graff‐Radford: h-index 131 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41513292) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_106309
- PubMed: 41513292
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.